Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Reduced Blood Lipid Levels With In Vivo CRISPR-Cas9 Base Editing of ANGPTL3.

Literature DB >> 29483174

Reduced Blood Lipid Levels With In Vivo CRISPR-Cas9 Base Editing of ANGPTL3.

Alexandra C Chadwick¹, Niklaus H Evitt¹, Wenjian Lv¹, Kiran Musunuru².

Abstract

Entities: CellLine Chemical Disease Gene Species

Keywords: ANGPTL3 protein, human; clustered regularly interspaced short palindromic repeats; coronary disease; lipids

Mesh：

Substances：

Year: 2018 PMID： 29483174 PMCID： PMC5830171 DOI： 10.1161/CIRCULATIONAHA.117.031335

Source DB: PubMed Journal: Circulation ISSN： 0009-7322 Impact factor: 29.690

× No keyword cloud information.

5 in total

1. PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE.

Authors: Brandon Ason; José W A van der Hoorn; Joyce Chan; Edward Lee; Elsbet J Pieterman; Kathy Khanh Nguyen; Mei Di; Susan Shetterly; Jie Tang; Wen-Chen Yeh; Margrit Schwarz; J Wouter Jukema; Rob Scott; Scott M Wasserman; Hans M G Princen; Simon Jackson
Journal: J Lipid Res Date: 2014-09-25 Impact factor: 5.922

2. In Vivo Base Editing of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) as a Therapeutic Alternative to Genome Editing.

Authors: Alexandra C Chadwick; Xiao Wang; Kiran Musunuru
Journal: Arterioscler Thromb Vasc Biol Date: 2017-07-27 Impact factor: 8.311

3. Cardiovascular endocrinology: Is ANGPTL3 the next PCSK9?

Authors: Kiran Musunuru; Sekar Kathiresan
Journal: Nat Rev Endocrinol Date: 2017-07-14 Impact factor: 43.330

4. Angiopoietin-like protein 3 supports the activity of hematopoietic stem cells in the bone marrow niche.

Authors: Junke Zheng; HoangDinh Huynh; Masato Umikawa; Robert Silvany; Cheng Cheng Zhang
Journal: Blood Date: 2010-10-19 Impact factor: 22.113

5. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage.

Authors: Alexis C Komor; Yongjoo B Kim; Michael S Packer; John A Zuris; David R Liu
Journal: Nature Date: 2016-04-20 Impact factor: 49.962

5 in total

40 in total

Review 1. Single-nucleotide editing: From principle, optimization to application.

Authors: Jinling Tang; Trevor Lee; Tao Sun
Journal: Hum Mutat Date: 2019-09-15 Impact factor: 4.878

2. Angiopoietin-like proteins as therapeutic targets for cardiovascular disease: focus on lipid disorders.

Authors: Marco Bruno Morelli; Christopher Chavez; Gaetano Santulli
Journal: Expert Opin Ther Targets Date: 2020-01-15 Impact factor: 6.902

3. Somatic Editing of Ldlr With Adeno-Associated Viral-CRISPR Is an Efficient Tool for Atherosclerosis Research.

Authors: Kelsey E Jarrett; Ciaran Lee; Marco De Giorgi; Ayrea Hurley; Baiba K Gillard; Alexandria M Doerfler; Ang Li; Henry J Pownall; Gang Bao; William R Lagor
Journal: Arterioscler Thromb Vasc Biol Date: 2018-09 Impact factor: 8.311

Review 4. Cholesterol Lowering Biotechnological Strategies: From Monoclonal Antibodies to Antisense Therapies. A Pre-Clinical Perspective Review.

Authors: S Bellosta; C Rossi; A S Alieva; A L Catapano; A Corsini; A Baragetti
Journal: Cardiovasc Drugs Ther Date: 2022-01-13 Impact factor: 3.727

5. Efficient in vivo base editing via single adeno-associated viruses with size-optimized genomes encoding compact adenine base editors.

Authors: Jessie R Davis; Xiao Wang; Isaac P Witte; Tony P Huang; Jonathan M Levy; Aditya Raguram; Samagya Banskota; Nabil G Seidah; Kiran Musunuru; David R Liu
Journal: Nat Biomed Eng Date: 2022-07-28 Impact factor: 29.234

Reduced Blood Lipid Levels With In Vivo CRISPR-Cas9 Base Editing of ANGPTL3.

1. PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE.

2. In Vivo Base Editing of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) as a Therapeutic Alternative to Genome Editing.

3. Cardiovascular endocrinology: Is ANGPTL3 the next PCSK9?

4. Angiopoietin-like protein 3 supports the activity of hematopoietic stem cells in the bone marrow niche.

5. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage.

Review 1. Single-nucleotide editing: From principle, optimization to application.

2. Angiopoietin-like proteins as therapeutic targets for cardiovascular disease: focus on lipid disorders.

3. Somatic Editing of Ldlr With Adeno-Associated Viral-CRISPR Is an Efficient Tool for Atherosclerosis Research.

Review 4. Cholesterol Lowering Biotechnological Strategies: From Monoclonal Antibodies to Antisense Therapies. A Pre-Clinical Perspective Review.

5. Efficient in vivo base editing via single adeno-associated viruses with size-optimized genomes encoding compact adenine base editors.

6. A Versatile Nonviral Delivery System for Multiplex Gene-Editing in the Liver.

7. Dyslipidaemia: In vivo genome editing of ANGPTL3: a therapy for atherosclerosis?

Review 8. Delivery approaches for CRISPR/Cas9 therapeutics in vivo: advances and challenges.

Review 9. Therapeutic genome editing in cardiovascular diseases.

10. Biotechnology Approaches for the Treatment of Dyslipidemia.